1861. Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Preliminary results from the Telavancin Observational Use Registry (TOUR™)
Session: Poster Abstract Session: Clinical Study with New Antibiotics and Antifungals
Saturday, October 7, 2017
Room: Poster Hall CD
  • Reilly_IDWeek 2017 Bacteremia Poster_Final_ 26Sep17.pdf (1.7 MB)
  • Background: Telavancin (TLV) is a lipoglycopeptide antibiotic active against Gram-positive pathogens, including methicillin-sensitive and -resistant Staphylococcus aureus (MSSA and MRSA). S. aureus bacteremia (SAB) can result in serious secondary infections such as infective endocarditis (IE). SAB treatment remains a major challenge and there is a need to identify effective treatments.

    Methods: The Telavancin Observational Use Registry (TOUR™) is a multicenter chart review study designed to characterize infection types, pathogens, and outcomes of patients treated with TLV in clinical practice. Data from TOUR were used to characterize a subset of patients with bacteremia and IE. Clinical data including patient demographics, pathogens, outcomes, and adverse events (AEs) were analyzed. Clinical outcomes were determined by investigators’ assessment.

    Results: As of March 31, 2017, data for more than 1000 patients were collected from 46 sites. Of these, 148 patients were treated for bacteremia and/or IE. Among these 148 patients, median age was 59 years (range 18−88 years) and 34% (n = 51) were aged ≥65 years, 55% (n = 81) were male, and 79% (n = 117) were White. The median body mass index was 27.3 kg/m2 (range 13.5−57.9 kg/m2). MRSA was the most commonly isolated pathogen at baseline (57%; n = 84). The median TLV daily dose and duration of treatment were 750 mg (range 250−1500 mg) or 8.9 mg/kg (range 2.9−15.0 mg/kg) and 9 days (range 1−70 days), respectively. Telavancin was used as second-line therapy in 85% (n = 126) of patients, and the majority of patients (78%; n = 115) were treated as inpatients. Overall, 66% (n = 97) of patients were cured or improved to step-down therapy, 9% (n = 13) failed treatment, 14% (n = 21) had an indeterminate clinical outcome at end of therapy (EOT), and 11% (n = 17) had missing or undocumented outcomes. Among the patients who had outcome assessment at EOT (n = 131), 74% were cured or improved to step-down therapy and 10% failed therapy. AEs were reported in 25 patients; 18 reported a serious AE, and 16 had AEs leading to TLV discontinuation.

    Conclusion: In a real-world setting, once-daily TLV produced positive clinical responses in patients with SAB and/or IE, and may represent an alternative treatment option in these serious infections.

    Joseph Reilly, PharmD, CGP1, Micah Jacobs, MD2, Asma Lat, PharmD3, Anna Osmukhina, PhD3 and Bibiana Castaneda-Ruiz, MD3, (1)Pharmacy, AtlantiCare Regional Medical Center, Atlantic City, NJ, (2)Romano Pontzer And Associates, Pittsburgh, PA, (3)Theravance Biopharma US, Inc., South San Francisco, CA


    J. Reilly, Theravance Biopharma US, Inc.: Scientific Advisor and Speaker's Bureau , Speaker honorarium

    M. Jacobs, Theravance Biopharma US, Inc.: Investigator and Speaker's Bureau , Research support and Speaker honorarium

    A. Lat, Theravance Biopharma US, Inc.: Employee and Shareholder , Salary

    A. Osmukhina, Theravance Biopharma US, Inc.: Employee and Shareholder , RSU, Stock Options and Salary

    B. Castaneda-Ruiz, Theravance Biopharma US, Inc.: Employee and Shareholder , Salary

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.